----
Current ValuationThe current P/E ratio is -124.17, within the reasonable range, cheaper than 79.57% of the time in the past 3 years, and the industry ranks 25/27, the industry Median 46.85.
-124.17xP/E
¥56.57Stock price
¥-0.46Earnings per share
-124.17xP/E
Stock price¥56.57Earnings per share¥-0.46
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -56.49x
- Typical range
- -124.39x–-29.35x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 46.85x
012243648
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 46.85x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
300347SZTigermed | -101.85x | 67.07% | ¥41.21B |
688114SHMGI | -124.17x | 67.24% | ¥23.56B |
688202SHMedicilon | -223.06x | -- | ¥10.29B |
688068SHHotgen | -25.13x | -- | ¥6.52B |
603108SHRunda Medical | -10.52x | 137.36% | ¥5.88B |
300463SZmaccura | -165.53x | 369.81% | ¥5.44B |
301096SZBio-S | -25.94x | -- | ¥4.62B |
688238SHOBiO Tech | -18.78x | 18.92% | ¥4.11B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
